6/25/2019 7:10:18 AM
Aldeyra Says Statistical Significance Not Achieved For Endpoints In SOLACE Trial
5/9/2019 7:14:58 AM
Aldeyra Therapeutics Q1 Loss Per Share $0.58 Vs Loss $0.43 Last Year
4/30/2019 8:16:16 AM
Aldeyra Therapeutics Says Last Patient Completed Dosing In SOLACE Phase 3 Clinical Trial
4/9/2019 8:02:53 AM
Aldeyra Therapeutics Announces Presentation Of Phase 2b Dry Eye Disease Results At 2019 ARVO Annual Meeting
4/2/2019 8:04:07 AM
Aldeyra Therapeutics Announces Enrollment Of First Patient Into RENEW Phase 3 Clinical Trial
3/26/2019 7:05:08 AM
Aldeyra Therapeutics Announces Positive Top-Line Results From Phase 3 ALLEVIATE Trial
3/8/2019 7:01:53 AM
Aldeyra Therapeutics FY Loss Per Share $1.79 Vs Loss $1.40 Last Year
1/15/2019 8:09:59 AM
Aldeyra Therapeutics Promotes Stephen Machatha To Position Of SVP Of Technical Operations
11/14/2018 7:11:44 AM
Aldeyra Therapeutics Q3 Loss Per Share $0.52 Vs Loss $0.32 Last Year
9/27/2018 8:43:24 PM
Aldeyra Therapeutics Prices Underwritten Public Offering Of 5.25 Mln Shares At $13.75/shr
9/26/2018 4:07:13 PM
Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock
9/26/2018 7:03:29 AM
Aldeyra Therapeutics Announces Positive Results From Phase 2b Dry Eye Disease Clinical Trial
9/25/2018 8:08:31 AM
Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented At IASLC
8/9/2018 7:33:18 AM
Aldeyra Therapeutics Q2 Loss Per Share $0.46 Vs Loss $0.35 Last Year
7/31/2018 8:03:52 AM
Aldeyra Therapeutics Names Joshua Reed As CFO
7/12/2018 8:05:27 AM
Aldeyra Therapeutics Announces Last Patient Dosed In Dry Eye Disease Phase 2b Clinical Trial